Zavicefta

Zavicefta

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ceftazidime pentahydrate 2,000 mg, avibactam Na 500 mg
Indications/Uses
In combination w/ metronidazole for complicated intra-abdominal infection (cIAI). Complicated UTI including pyelonephritis (cUTI); hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP).
Dosage/Direction for Use
cIAI 1 vial every 8 hr over 2 hr for 5-14 days. cUTI including pyelonephritis 1 vial every 8 hr over 2 hr for 5-10 days, may be increased up to 14 days in patient w/ bacteraemia. HAP including VAP 1 vial every 8 hr over 2 hr for 7-14 days. Renal impairment CrCl 31-50 mL/min 1,000 mg/250 mg every 8 hr over 2 hr, 16-30 mL/min 750 mg/187.5 mg every 12 hr over 2 hr, 6-15 mL/min 750 mg/187.5 mg every 24 hr over 2 hr, ESRD including on haemodialysis 750 mg/187.5 mg every 48 hr over 2 hr.
Contraindications
Hypersensitivity to ceftazidime pentahydrate, avibactam Na or any cephalosporins. Severe hypersensitivity (eg, anaphylactic & severe skin reaction) to any other β-lactams eg, penicillins, monobactams or carbapenems.
Special Precautions
Discontinue use if hypersensitivity reactions; severe cutaneous adverse reactions eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction w/ eosinophilia & systemic symptoms; acute generalised exanthematous pustulosis occur. Hypersensitivity reactions to penicillins, cephalosporins, carbapenems or other β-lactam agents. Clostridium difficile-associated diarrhoea; nephrotoxicity; overgrowth of non-susceptible organisms. May cause positive direct antiglobulin or Coombs' test, drug-induced immune haemolytic anaemia. Prolonged use. Patients on controlled Na diet. Medicinal products inhibiting peristalsis is not to be given. Concurrent use w/ nephrotoxic drugs eg, aminoglycosides or potent diuretics (eg, furosemide). Interference w/ copper reduction methods for glycosuria detection. May affect ability to drive & use machines. Renal impairment. Pregnancy & lactation. Childn & adolescents <18 yr.
Adverse Reactions
Coombs' positive direct test; nausea, diarrhoea. Candidiasis; eosinophilia, thrombocytosis, thrombocytopenia; headache, dizziness; abdominal pain, vomiting; increased alanine & aspartate aminotransferase, blood alkaline phosphatase & lactate dehydrogenase, γ-glutamyltransferase; maculopapular rash, urticaria, pruritus; infusion site thrombosis & phlebitis, pyrexia.
Drug Interactions
Altered elimination w/ probenecid. Adversely affected renal function w/ nephrotoxic drugs eg, aminoglycosides or potent diuretics (eg, furosemide). Antagonism w/ chloramphenicol.
MIMS Class
ATC Classification
J01DD52 - ceftazidime and beta-lactamase inhibitor ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Presentation/Packing
Form
Zavicefta powd for infusion
Packing/Price
20 mL x 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in